<b>Format of the Annual Disclosure to be made by an entity identified as a Large Corporate.</b><br/><br/> <table border=''1px''> <tr> <td><b>Sr. No.</b></td> <td><b>Particulars</b></td> ....
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Aspira Pathlab & Diagnostics Ltd has informed BSE that it does not qualify as a 'Large Corporate' under SEBI's criteria (Circular SEBI/HO/DDHS/CIR/P/2018/144 dated November 26, 2018). Therefore, the mandatory Annual Disclosure in Annexure B2 regarding debt security fundraising for FY 2024-2025 is not applicable to the company. The filing was signed by the CFO and Company Secretary on April 14, 2025. This is a routine regulatory compliance submission.
No material impact on shareholders or stock price. This is a standard compliance filing confirming the company falls below the Large Corporate threshold, meaning it is not required to make mandatory debt fundraising disclosures.